ATE401890T1 - Formulierung mit kontrollierten freisetzung enthaltend lamotrigin - Google Patents

Formulierung mit kontrollierten freisetzung enthaltend lamotrigin

Info

Publication number
ATE401890T1
ATE401890T1 AT03748504T AT03748504T ATE401890T1 AT E401890 T1 ATE401890 T1 AT E401890T1 AT 03748504 T AT03748504 T AT 03748504T AT 03748504 T AT03748504 T AT 03748504T AT E401890 T1 ATE401890 T1 AT E401890T1
Authority
AT
Austria
Prior art keywords
controlled release
release formulation
formulation containing
formulations
lamotrigine
Prior art date
Application number
AT03748504T
Other languages
English (en)
Inventor
Sunil Sadanand Nadkarni
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE401890T1 publication Critical patent/ATE401890T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT03748504T 2002-06-07 2003-06-06 Formulierung mit kontrollierten freisetzung enthaltend lamotrigin ATE401890T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38679502P 2002-06-07 2002-06-07

Publications (1)

Publication Number Publication Date
ATE401890T1 true ATE401890T1 (de) 2008-08-15

Family

ID=29736213

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03748504T ATE401890T1 (de) 2002-06-07 2003-06-06 Formulierung mit kontrollierten freisetzung enthaltend lamotrigin

Country Status (12)

Country Link
US (2) US7939102B2 (de)
EP (1) EP1513535B1 (de)
AT (1) ATE401890T1 (de)
AU (1) AU2003267808A1 (de)
BR (1) BRPI0311701B8 (de)
CA (1) CA2488868C (de)
DE (1) DE60322389D1 (de)
DK (1) DK1513535T3 (de)
ES (1) ES2311108T3 (de)
PT (1) PT1513535E (de)
RU (1) RU2328274C2 (de)
WO (1) WO2003104192A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE348618T1 (de) * 2001-05-09 2007-01-15 Bayer Healthcare Ag Neue verwendung von 2-(2-ethoxy-5-(4-methyl- piperazin-1-sulfonyl)-phenyl)-5-methyl-7-propyl 3h-imidazo(5,1-f)(1,2,4)triazin-4-on
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
WO2004103340A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
WO2005051350A2 (en) * 2003-10-28 2005-06-09 Torrent Pharmaceuticals Limited Water dispersible tablet
AU2005244329A1 (en) * 2004-04-06 2005-11-24 Rpg Life Sciences Limited Mouth dissolvable and meltable, and water dispersable delivery formulation
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
WO2006088814A2 (en) * 2005-02-15 2006-08-24 Jazz Pharmaceuticals Dosage form and method for sustained release of a substituted pyrazine compound
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
WO2006092064A1 (en) * 2005-03-04 2006-09-08 Intelgenx Corporation Delayed release pharmaceutical oral dosage form and method of making same
EP1906937B1 (de) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Neuartige dispergierbare tabletten zusammensetzung
US20090186896A1 (en) * 2005-09-29 2009-07-23 Bayer Healthcare Ag PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders
CA2689638A1 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
TWI547282B (zh) * 2007-07-02 2016-09-01 愛戴爾製藥股份有限公司 樂命達之口服分解錠劑組合物
US20090022789A1 (en) * 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
US20090181084A1 (en) * 2008-01-15 2009-07-16 Ta-Ping Liao Oral fast-disintegrating tablet including particles of slowly-releaseable ascorbic acid
US20090196924A1 (en) * 2008-02-04 2009-08-06 Pramod Kharwade Controlled-release lamotrigine formulations
US8133506B2 (en) 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
FR2930147B1 (fr) * 2008-04-18 2013-02-08 Flamel Tech Sa Forme orale solide dotee d'un double profil de liberation
AU2010211985A1 (en) * 2009-01-22 2011-08-11 Abbott Healthcare Private Limited Chronotherapeutic pharmaceutical composition
EP2263657B1 (de) 2009-05-20 2013-07-17 Ranbaxy Laboratories Limited Lamotriginformulierungen mit gesteuerter Freisetzung
US20110052686A1 (en) 2009-09-03 2011-03-03 Ranbaxy Laboratories Limited Modified release lamotrigine tablets
EP2542243A2 (de) 2010-03-04 2013-01-09 Wockhardt Limited Darreichungsform mit modifizierter freisetzung
RU2633655C1 (ru) * 2016-05-17 2017-10-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" Устройство для дозированного вскрытия микрокапсул
CN110545818A (zh) * 2017-02-03 2019-12-06 朱比兰特医药有限公司 拉莫三嗪悬浮剂剂型

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE66933B1 (en) 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
IL100796A (en) 1991-01-30 1998-09-24 Wellcome Found Water-dispersed tablets containing acyclovir or lemotrigin
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
ES2282628T3 (es) * 2002-04-23 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicon farmaceutica que contiene particulas de lamotrigina de morfologia definida.
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
WO2004012741A1 (en) 2002-07-29 2004-02-12 Glaxo Group Limited Sustained release formulations comprising lamotrigine

Also Published As

Publication number Publication date
WO2003104192A2 (en) 2003-12-18
RU2328274C2 (ru) 2008-07-10
CA2488868A1 (en) 2003-12-18
BR0311701A (pt) 2005-03-08
US20110123618A1 (en) 2011-05-26
US7939102B2 (en) 2011-05-10
EP1513535A2 (de) 2005-03-16
BRPI0311701B1 (pt) 2018-05-29
DK1513535T3 (da) 2008-11-17
EP1513535B1 (de) 2008-07-23
AU2003267808A1 (en) 2003-12-22
CA2488868C (en) 2010-05-11
PT1513535E (pt) 2008-10-31
ES2311108T3 (es) 2009-02-01
US20040043996A1 (en) 2004-03-04
AU2003267808A8 (en) 2003-12-22
WO2003104192A3 (en) 2004-03-11
DE60322389D1 (de) 2008-09-04
RU2004139088A (ru) 2005-11-20
BRPI0311701B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
ATE401890T1 (de) Formulierung mit kontrollierten freisetzung enthaltend lamotrigin
IL280818A (en) Methods of production of alpha-galactosides preparations
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
DK0703786T3 (da) Anvendelse af nona- og dekapeptider til fremstilling af et lægemiddel til behandling af AIDS
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
AU2003245282A1 (en) Stent coatings with sustained drug release rate
MXPA04011612A (es) Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
HUP0401978A2 (hu) Tamszulozintabletták
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
ATE376832T1 (de) Verzögert freisetzende formulierungen von oxymorphon
AU7031500A (en) Therapeutic quinazoline compounds
GB0128108D0 (en) Therapeutic use
PT998287E (pt) Utilizacao de levobupivacaina
NO20051658L (no) Terapeutisk behandling
WO2005055955A3 (en) DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY
NO331082B1 (no) Formulering av kahalalid F, sett omfattende en slik formulering, samt rekonstituert losning derav og anvendelse av en fortynnet rekonstituert losning til fremstilling av et medikament for behandling av kreft
AU2003271021A1 (en) Immunogen for preparation of therapeutic vaccines or drugs for treatment of hepatitis b and the producing method and use thereof
WO2003039539A3 (de) Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen
MY136059A (en) Swallow tablet comprising paracetamol
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
HUP0401782A2 (hu) Új, vízmentes kristályos gabapentin formák
SE0102887D0 (sv) New formulation
MXPA01007952A (es) Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties